Chest, Vol 101, 309-315, Copyright © 1992 by American College of Chest Physicians

ARTICLES

Relative amount of albuterol delivered to lung receptors from a metered- dose inhaler and nebulizer solution. Bioassay by histamine bronchoprovocation

KV Blake, M Hoppe, E Harman and L Hendeles
Department of Pharmacy Practice, College of Pharmacy, University of Florida, Gainesville.

The results of previous studies comparing bronchodilatation from beta agonists administered by metered-dose inhaler (MDI) and nebulizer solution have been conflicting. We therefore evaluated a range of albuterol doses administered by these two methods, using histamine bronchoprovocation as a bioassay for the amount of drug reaching the beta 2 receptors in the lung. Twelve stable asthmatic volunteers received, in a double-blind, randomized, crossover design on different days, placebo or one, two, four, or six puffs from an MDI attached to an InspirEase device (90 micrograms per puff) or 0.625, 1.25, 2.5, or 5.0 mg of solution delivered in 2 ml of buffered saline through a Hudson Updraft II nebulizer. The histamine concentration required to decrease FEV1 by 20 percent (PC20) was measured 1 h before and 30 min after administration of each treatment and expressed as the increase in PC20 from baseline. The dose-response curves for change in PC20 indicated that the higher doses of the nebulizer solution delivered more drug to beta 2 receptors in the lung than the lower doses from the MDI. For example, the geometric mean increase in PC20 was 1.1 +/- 1.6 (SD) after placebo, 7.5 +/- 2.7 after two puffs from the MDI, and 20.0 +/- 2.1 after 2.5 mg of nebulizer solution (p less than 0.05). Using this bioassay method and administration technique, we estimated that ten puffs from the MDI (0.9 mg) would deliver approximately the same amount of albuterol to lung receptors as 2.5 mg of the nebulizer solution. Taking into account previously published reports and the results of the present study, we conclude that differences in dose, administration technique, nebulizer system efficiency, and severity of airway obstruction can alter the amount of drug reaching the beta 2 receptors in the lungs and, thus, the clinical response.

This article has been cited by other articles:

				R Boyd and P Stuart Pressurised metered dose inhalers with spacers versus nebulisers for {beta}-agonist delivery in acute asthma in children in the emergency department Emerg. Med. J., September 1, 2005; 22(9): 641 - 642. [Abstract] [Full Text] [PDF]

				L. Hendeles, R. C. Hatton, T. J. Coons, and L. Carlson Automatic replacement of albuterol nebulizer therapy by metered-dose inhaler and valved holding chamber Am. J. Health Syst. Pharm., May 15, 2005; 62(10): 1053 - 1061. [Abstract] [Full Text] [PDF]

				M. B. Dolovich, R. C. Ahrens, D. R. Hess, P. Anderson, R. Dhand, J. L. Rau, G. C. Smaldone, and G. Guyatt Device Selection and Outcomes of Aerosol Therapy: Evidence-Based Guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology Chest, January 1, 2005; 127(1): 335 - 371. [Abstract] [Full Text] [PDF]

				M.T. Newhouse, P. Patel, and M. Parry-Billings Protection against methacholine-induced bronchospasm: salbutamol pMDI versus Clickhaler(R) DPI Eur. Respir. J., May 1, 2003; 21(5): 816 - 820. [Abstract] [Full Text] [PDF]

				B. A. Stewart, R. C. Ahrens, S. Carrier, M. Frosolono, C. Lux, S.-H. Han, and G. Milavetz Demonstration of In Vivo Bioequivalence of a Generic Albuterol Metered-Dose Inhaler to Ventolin Chest, March 1, 2000; 117(3): 714 - 721. [Abstract] [Full Text] [PDF]

				A L Dewar, A Stewart, J J Cogswell, and G J Connett A randomised controlled trial to assess the relative benefits of large volume spacers and nebulisers to treat acute asthma in hospital Arch. Dis. Child., May 1, 1999; 80(5): 421 - 423. [Abstract] [Full Text]

				P. Marshik, S. Moghaddam, I. Tebbett, and L. Hendeles Degradation of Histamine Solutions Used for Bronchoprovocation Chest, January 1, 1999; 115(1): 194 - 199. [Abstract] [Full Text] [PDF]